⚠️ Small Study / Early Comparative Evidence
A published case report described an exceptional response to sodium selenite in advanced progressive lung cancer. Investigators also observed a marked sPD-L1 decrease during treatment.
Clinical Considerations
- One patient achieved complete tumor disappearance and remained tumor-free for 10 years.
- The uncontrolled report cannot separate treatment effect from tumor biology, prior therapies, or other factors.
- The sPD-L1 decline offers mechanistic interest but does not establish immune activation or treatment response.
- Claims regarding tolerability, affordability, and global applicability require evaluation in larger controlled studies.
Practice Applications
- Recognize the result as an exceptional case rather than evidence of efficacy.
- Avoid extrapolating this outcome to selenium supplements or routine cancer care.
- Interpret sPD-L1 changes as exploratory biomarker observations.
- Monitor planned clinical studies evaluating selenite in larger populations.
PATIENT EDUCATION
OBESITY/WEIGHT MANAGEMENT
EXERCISE/TRAINING
LEGAL MATTERS
GUIDELINES/RECOMMENDATIONS